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1. Introduction
The liver is the largest gland in the body. The average human liver weighs approximately
1.5-1.7 kg, and holds a blood volume of approximately 500 ml. It receives approximately
25% of the cardiac output, of which 75% is supplied by the portal vein and the other 25% by
the hepatic artery. Its venous drainage is to the inferior vena cava via the hepatic veins. The
hepatic ductal system produces the bile which is then stored in the gall bladder.
The liver synthesizes most proteins, with the exception of gamma globulins and factor VIII.
It is also responsible for protein degradation, glucose homeostasis, fatty acid β-oxidation, bi‐
lirubin production and excretion. Hepatocytes are embryologically less differentiated; hence
the liver is the only organ capable of regeneration after surgical resection or trauma.
Hepatic blood flow is predominantly dependent upon systemic blood flow and pressure-
based on pressure flow regulation and hepatic arterial buffer response. There is also central
nervous system control of the hepatic blood flow via the thoracic sympathetic fibers. Sympa‐
thetic stimulation may cause the blood volume which is present in the liver to be expelled
into the circulation, thus providing additional circulatory volume if needed.
Hepatic blood flow is reduced by all anesthetic agents and techniques via reductions in hep‐
atic blood flow and hepatic oxygen uptake. The volatile agents, desflurane and sevoflurane
have the least significant effect on total hepatic blood flow. Other perioperative causes of a
reduction of hepatic blood flow include mechanical ventilation, hypercarbia, positive end-
expiratory pressure, hypotension, hemorrhage, hypoxemia and surgery. A significant de‐
crease in hepatic blood flow can result in parenchymal centrilobular necrosis when extreme
resulting in further worsening of perioperative liver dysfunction.
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In liver disease, anesthetic drug distribution, metabolism and elimination may be altered.
Uptake and onset of anesthetic drug action is usually unaffected. Hepatic clearance of an
agent is dependent upon volume of distribution, functional hepatic blood flow, hepatic ex‐
traction ratio and hepatic microsomal activity. As a result, opioids may accumulate and the
pharmacological actions of drugs such as benzodiazepines maybe prolonged. In extreme sit‐
uations, actions of non-depolarizing muscle relaxants such as vecuronium and rocuronium
maybe also be prolonged.
The liver plays a critical role in coagulation as it is the principal site of synthesis for the ma‐
jority of clotting factors: II, V, VII, IX, X, XI, and XII. All coagulation factors except for VIII,
which is mainly produced by the endothelium, are markedly reduced in patients with liver
disease. Patients with chronic liver disease may also develop thrombocytopenia secondary
to splenomegaly caused by prolonged portal hypertension. Additionally, reduced levels of
thrombopoietin, which regulates platelet production in the liver, may also further contribute
to platelet counts in more advanced disease. Also, antithrombin-III (AT-III) levels fall due to
reduced synthesis and/or increased consumption due to fibrinolysis. All of the proteins in‐
volved in fibrinolysis except for tissue plasminogen activator (tPA) and plasminogen activa‐
tor inhibitor (PAI-1) are synthesized in the liver. However, tPA levels can be increased due
to decreased clearance by the liver predisposing patients to further risks of intra- and perio‐
perative hemorrhage. Hemostatic changes associated with surgical bleeding are thrombocy‐
topenia, platelet function defects, inhibition of platelet aggregation and adhesion by nitric
oxide and prostacyclin, decreased levels of coagulation factors: II, V, VII, IX, X, XI, quantita‐
tive and qualitative abnormalities of fibrinogen, low levels of α2-antiplasmin, Factor XIII
and thrombin activatable fibrinolysis inhibitor, and elevated tPA. Hemostatic changes asso‐
ciated with thrombosis are elevated vWF, decreased levels of ADAMTS-13 (a vWF cleaving
protease), and decreased levels of anti-coagulants: ATIII, Protein C and S, α2 macroglobulin,
elevated levels of heparin cofactor II, elevated VIII, decreased levels of plasminogen, normal
or increased PAI-1. Hypercoagulability can occur in patients with liver disease, especially
those with cholestatic disease.
In  the  setting  of  acute  liver  failure  (ALF),  the  coagulopathy  encountered  can  be  much
more severe.  Plasma concentrations of  coagulation factors  with the shortest  half-life  fall
first;  factors  V and VII  (12  hrs  and 4-6hrs  respectively)  and factors  II,VII  and X subse‐
quently. In a review of over 1000 patients with ALF by the US Acute Liver Failure Study
Group,  the  mean  international  normalization  ratio  (INR)  in  ALF was  3.8  +/-  4.0  (range
1.5 - >10) with most having a moderately prolonged INR (1.5 to 5) and only 19% with an
INR  >5.  Moreover,  thrombocytopenia  is  common  with  40%  of  patients  having  platelet
counts < 90,000 on admission. [1]
2. Pathophysiology of End Stage Liver Disease
Liver disease can be acute or chronic. Common causes of chronic liver disease are viral hep‐
atitis (B & C), autoimmune hepatitis, non-alcoholic steatohepatitis (NASH), Laennec’s cir‐
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rhosis, cryptogenic cirrhosis, and metabolic diseases such as hemachromatosis and Wilson’s
disease. Cholestatic causes of liver disease include primary biliary cirrhosis and primary
sclerosing cholangitis.
Predominant pathophysiological manifestation of liver disease is portal hypertension. There
is increased resistance to portal blood flow due to hepatic parenchymal scarring and fibro‐
sis, and splanchnic hyperemic resulting in hypersplenism, thrombocytopenia and the pro‐
gression formation of varices. Normal portal pressures are usually in the range of 5-12
mmHg. Portal hypertension is generally defined when any 2 of the following 3 criteria are
met: splenomegaly, ascites or bleeding esophageal varices. Portal pressures at this time are
usually > 20 mmHg.
The combination of decreased production of albumin and portal hypertension results in the
accumulation of ascites. It also occurs due to renal retention of sodium and water, and local‐
ization of this excess fluid in the peritoneal cavity. Tense ascites may decrease functional re‐
sidual capacity (FRC), adversely affect pulmonary gas exchange and increase risk of
aspiration. Hydrothorax or pleural effusions may produce atelectasis. Secondary hyperal‐
dosteronism may manifest as hypokalemic metabolic alkalosis. Additionally, there is intra-
and extra-pulmonary shunting, elevated mixed venous oxygen saturation (SvO2), altered
lactate metabolism. The hyperdynamic circulation is a result of decreased systemic vascular
resistance (SVR) and compensatory increased cardiac output to maintain tissue perfusion.
Inadequate synthesis of coagulation factors produces coagulopathy. There is delayed gastric
emptying creating putting the patient at-risk for aspiration. Increased ammonia levels (hy‐
perammonemia) can result in hepatic encephalopathy.
3. Other clinically relevant associations with patients with liver disease
includes
Portopulmonary hypertension (POPH) is a pulmonary hypertension syndrome with vascu‐
lar obstruction and increased resistance to pulmonary arterial flow due to varying degrees
of pulmonary endothelial/smooth muscle proliferation, vasoconstriction and in-situ throm‐
bosis. The development of POPH has not been demonstrated to correlate with the severity
of liver disease.
Hepatopulmonary syndrome (HPS) is characterized by arterial hypoxemia caused by intra-
pulmonary vascular dilatations. The clinical triad of 1) portal hypertension; 2) hypoxemia;
and 3) pulmonary vascular dilatations characterizes the clinical presentation of HPS [2].
Hepatorenal syndrome is a form of pre-renal acute kidney injury that occurs in decompen‐
sated cirrhosis. The syndrome is classified into two types: Type 1 is characterized by a dou‐
bling of the serum creatinine level to greater than 2.5 mg/dl in less than 2 weeks while Type
2 is characterized by a stable or slower progressive course of renal failure [3].
Hepatic encephalopathy occurs due to accumulation of circulating neurotoxins such as un‐
metabolized ammonia, gamma aminobutyric acid, gut-derived false neurotransmitters lead‐
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ing to altered neurotransmission by glutamate or altered cerebral energy homeostatsis. [4]
Clinically, it is manifested by neuropsychiatric abnormalities and generalized clonus on clin‐
ical examination.
4. Assessing perioperative risk
Patient operative risk is dictated by severity of liver disease, co-existing medical diseases
and type of surgery (i.e., upper abdominal, emergent, cardiac etc.) It may also be dependent
on s on the anesthetic conducted and ability to maintain of hepatic blood flow.
An important measure for assessing mortality risk is the Child-Pugh Classification. Though this
was first used to stratify risk for surgical correction of portal hypertension, it is also found to be
predictive of survival in cirrhosis. The score is assigned based upon bilirubin, albumin, pro‐
thrombin time (PT), ascites and encephalopathy. One point is given for each of the following: al‐
bumin > 3.5 g/dl, INR < 1.7, bilirubin <2mg/dl, no ascites, no encephalopathy. 2 points are given
for each of the following: Albumin 1.8- 3.5 g/dl, INR between1.7-2.3, bilirubin 2-3 mg/dl, slight to
moderate ascites, grade 1-2 encephalopathy. 3 points are given for each of the following: albu‐
min < 1.8 g/dl, INR >2.3, bilirubin > 3 mg/dl, tense ascites, grade 3-4 encephalopathy. Class A = 5-6
points, Class B = 7-9 points, Class C = 10-15 points. [5] Child Pugh A, B, C predicts a perioperative
mortality risk of 10, 30 and 80 % respectively. [6]
Other measures for predicting mortality include ascites, increased serum creatinine, preop‐
erative GI bleed, high ASA physical status score and previous abdominal surgery. Steatosis
and steatohepatitis may also be considered as risk factors for postoperative complications,
especially after abdominal procedures. The Model of End Liver Disease (MELD) score pre‐
dicts severity based upon serum creatinine, total bilirubin, and PT INR. It is used to estimate
long term survival, as well as list patients for liver transplantation with the United network
of Organ Sharing (UNOS). (need a reference here)
Elective surgery is contraindicated when the patient has acute viral hepatitis, alcoholic hepa‐
titis, fulminant hepatic failure, severe chronic hepatitis, is a Child Pugh C patient or has oth‐
er manifestations of end stage liver disease.
Patients with advanced liver disease should be effectively managed so that hepatic perfusion
and hepatic oxygen delivery are maximized l and sequelae of their liver disease such as hepatic
encephalopathy, cerebral edema, coagulopathy, hepatopulmonary syndrome, portopulmona‐
ry hypertension and portal hypertension has been identified and treated accordingly if possible.
5. Preoperative evaluation of patients with liver disease
Assessment of hepatic function includes evaluating risks for aggravating underlying liver
disease, extra-hepatic complications, alterations of hepatic synthetic function and altered
drug disposition.
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Liver function tests do not measure hepatic function. They represent release of damaged or
dead hepatocyte intracellular contents into the systemic circulation, hence provide a snap‐
shot at that point in time only. Actual liver function is represented by albumin, prothrombin
time and pseudocholinesterase concentrations. Obtaining liver function tests in healthy pa‐
tients is not recommended as abnormal liver function tests (LFTs) exist in about 1 in 700 pa‐
tients, and a vast majority of these patients do not have advanced liver disease. Thus,
patients with asymptomatic elevations in serum transaminase levels (less than two times
normal values) may undergo anesthesia and surgery with good outcomes.
Patients with chronic hepatitis should be screened prior to elective surgery even if they are
asymptomatic. The INR is the most sensitive indicator of hepatocellular dysfunction. At
present, though it is accepted that abnormal hemostasis is a result of liver disease, it is de‐
batable whether the abnormal tests really predict bleeding risk [7]. Moreover, the relation‐
ship of coagulation profiles to the risk of bleeding with chronic as well as acute liver disease
is uncertain [8]. Low platelet count may not be solely responsible for an increased risk of
bleeding as the platelet function is also important. Bleeding time is no longer recommended
as a test of platelet function. The current consensus is for a pre-procedure platelet count >
50,000, since it appears that a platelet count above 50,000 is likely to be adequate based on
previous studies [9].
It is also important to assess the patient for extra-hepatic pathophysiology related to liver
disease. The diagnostic criteria for POPH include a mean pulmonary artery pressure
(mPAP) greater than 25 mmHg at rest and a pulmonary vascular resistance (PVR) of > 240
dynes.s.cm-5 [10]. A better measure is a transpulmonary gradient > 12 mmHg (mPAP-PAOP)
as this reflects the obstruction to flow (PVR) and also distinguishes the contribution of intra‐
vascular volume and flow to the mPAP [11].
The European Respiratory Society (ERS)/European Association for Study of the Liver
(EASL) Task Force have certain set diagnostic criteria for hepatopulmonary syndrome
(HPS). These include diagnosis of liver disease, an A-a oxygen gradient > 15 mmHg, pulmo‐
nary vascular dilatation documented by “positive" delayed, contrast-enhanced echocardiog‐
raphy with left heart, detection of microbubbles for > 4 cardiac cycles after right heart
opacification of microbubbles and brain uptake > 6% following 99mTc macroaggregated al‐
bumin (MAA) lung perfusion scanning. HPS can be diagnosed when there is a cirrhosis
with ascites, serum creatinine of >1.5 mg/dL, no improvement of serum creatinine after at
least 2 days with diuretic withdrawal and volume expansion with albumin, absence of
shock, no current or recent treatment with nephrotoxic drugs and absence of parenchymal
kidney disease as indicated by proteinuria > 500 mg/day, microhematuria, and/or abnormal
renal ultrasonography. [12]
6. Cardiac assessment of End Stage Liver Disease (ESLD) patients
Cirrhotic patients with ESLD may suffer from cirrhotic cardiomyopathy. This is comprised
of increased cardiac output and compromised ventricular response to stress. This entity is
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likely mediated by decreased beta-agonist transduction, increased circulating inflammatory
mediators resulting in cardiac depression, and accompanying repolarization abnormalities
[13-18]. Low systemic vascular resistance and bradycardia are also commonly seen in ESLD.
Patients with ESLD may also demonstrate diastolic dysfunction. [19]. The electrophysiologic
abnormalities found in cirrhotic cardiomyopathy include QT-interval prolongation, electri‐
cal and mechanical dyssynchrony and chronotropic incompetence [20-22]. Carvedilol ad‐
ministered to patients with ESLD has been demonstrated to reduce portal pressures by
decreasing net splanchnic blood flow. [23].
Additionally,  ESLD  are  also  at  risk  for  the  development  of  coronary  artery  disease
(CAD),  however  the  liver  itself  has  not  been  implicated.  Approximately  25  %  of  these
patients have at  least  one moderate or severe coronary artery with critical  stenosis.  Ob‐
structive CAD was most  common among patients with 2 traditional  cardiac risk factors
such as smoking, diabetes mellitus ( DM),and/or hyperlipidemia [24]. Left ventricular hy‐
pertrophy and hyperdynamic systolic  function in ESLD may result  in hemodynamically
significant  left  ventricular  outflow tract  obstruction  (LVOTO).  One  retrospective  review
of 106 transplant recipients found inducible LVOTO on pre-operative dobutamine stress
echocardiography (DSE) in 40% of patients [25]. In this study, an outflow gradient of 36
mm  Hg  was  significantly  associated  with  intraoperative  hypotension.  Many  ESLD  pa‐
tients  also  have  prolonged  corrected  QT  interval  (QTc)  on  an  electrocardiogram  which
can be  associated with  an increased risk  of  ventricular  arrhythmias.  Though it  is  not  a
contraindication to  surgery  and anesthesia,  one  should look for  electrolyte  disturbances
or  the  use  of  QT  interval-prolonging  drugs.  All  patients  with  ESLD should  undergo  a
preoperative  echocardiography  to  assess  ventricular  function,  ventricular  size,  valvular
function, pulmonary artery pressure, and to exclude the presence of a significant LVOTO
or pericardial  effusion.  Pre-operative  echocardiography is  useful  to  calculate  pulmonary
artery  systolic  pressure.  Pulmonary  artery  systolic  pressures  (PASP)  values  of  45-50
mmHg and /or right ventricular dysfunction are usually used for screening POPH. Right
heart catheterization should be performed to gauge the mean pulmonary artery pressure
(PAP), pulmonary capillary wedge pressure (PCWP) and transpulmonary gradient (TPG)
as  5% to  10% of  ESLD candidates  have  POPH [26],.  A preoperative  mPAP of  35  to  50
mm Hg has  been  associated  with  a  50% risk  of  mortality  after  liver  transplantation  in
patients  with  POPH  [26],  and  mortality  approached  100%  among  patients  with  POPH
and mPAP ≥50 mm Hg [27]. Thus, POPH warrants perioperative treatment with vasodi‐
lators  such  as  epoprosterenol,  sildenafil  or  nitric  oxide.  Stress  testing  of  ESLD patients
can  be  done  to  detect  CAD.  Dobutamine  stress  echocardiography  has  been  found  to
have a negative predictive value in ESLD patients to be 85%.[28,29]. The predictive value
of nuclear single-photon emission computed tomography (SPECT) stress imaging is limit‐
ed by the chronic vasodilatory state exhibited by patients with ESLD [30]. The specificity
of abnormal SPECT findings for obstructive CAD by coronary angiography is  only 61%
[31]. Coronary angiography is the gold standard for detecting CAD. When possible, it is
important make an assessment of CAD risk in the ESLD patient before revascularization
becomes contraindicated (usually an excessive bleeding risk due to coagulopathy and/or
thrombocytopenia).  Transesophageal  echocardiography  (TEE)  and/or  pulmonary  artery
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catheterization may be used intraoperatively to  allow for  real-time hemodynamic moni‐
toring and volume management..
7. Anesthetic agents
All volatile anesthetics decrease the mean arterial pressure and portal blood flow. Halothane
has consistently the most dramatic effect in reducing hepatic arterial blood flow. [32,33]. On
the other hand, sevoflurane, desflurane and isoflurane have been consistently shown to bet‐
ter preserve hepatic blood flow and function. Intravenous anesthetics have a modest impact
on hepatic blood flow, and no meaningful adverse impact on postoperative liver function if
the mean arterial pressure is adequately maintained throughout the time anesthetized. In‐
duction agents such as etomidate and thiopental decrease hepatic blood flow, either from
increased hepatic arterial vascular resistance or from reduced cardiac output and/or blood
pressure. [34]. Ketamine has little impact on hepatic blood flow. [35] Propofol increases total
hepatic blood flow in both hepatic arterial and portal venous circulation, suggesting a signif‐
icant vasodilator effect. [36,37].
Opioids such as morphine have significantly reduced metabolism in patients with advanced
cirrhosis. The elimination half-life of morphine is prolonged, potentially exaggerating seda‐
tive and respiratory depressant effects. Fentanyl is highly lipid soluble with a short duration
of action, which is also metabolized in the liver. Fentanyl elimination is not appreciably al‐
tered in patients with cirrhosis. [38,39]. However, unlike fentanyl, the half-life of alfentanil is
almost doubled in patients with cirrhosis. [40]. Remifentanil is a synthetic opioid with an es‐
ter linkage that allows for rapid hydrolysis by blood and tissue esterases. It elimination is
unaltered in patients with severe liver disease. [41].
Thiopental has a small hepatic extraction ratio. However, its elimination half-life is un‐
changed in cirrhotics, as it has a large volume of distribution. The clearance of etomidate is
unchanged in cirrhotic patients, but its clinical recovery time maybe unpredictable due to
increased volumes of distribution [42]. The elimination kinetic profile of propofol is similar
in cirrhotic patients as well as normal patients, but the mean clinical recovery times maybe
longer after discontinuation of infusions. [43]. The half-life of midazolam is prolonged due
to reduced clearance, reduced protein binding, resulting in a prolonged duration of action
and an enhanced sedative effect, especially after multiple doses or prolonged infusions. [44]
Dexmedetomidine, an α2-adrenergic agonist, with sedative and analgesic properties, is pri‐
marily metabolized in the liver. Dose adjustments are therefore indicated when used in pa‐
tients with significant hepatic dysfunction. [45].
Vecuronium and rocuronium are steroidal muscle relaxants which undergo hepatic metabo‐
lism, hence have decreased clearance, prolonged half-lives, and prolonged neuromuscular
blockade in patients with cirrhosis. [46,47]. Atracurium and cisatracurium which undergo
Hofmann elimination and ester hydrolysis respectively, have clinical duration of actions
similar to those in normal patients. [48,49]




For liver surgery where major bleeding is anticipated, it is prudent to secure intravenous
access  using  large  bore  peripheral  catheters  as  well  as  central  venous  access  catheters.
Rapid sequence induction is recommended in patients with tense ascites to minimize the
risk  of  aspiration.  Circulatory  collapse  should be  prevented by concomitant  administra‐
tion of  intravenous colloid solutions because intravascular volume re-equilibrium occurs
6 to 8 hrs after removal of larger volumes of ascitic fluid. [50]. Large volumes of colloids
and crystalloids maybe given within a few minutes with the assistance of  commercially
available  rapid infusion devices.  Red cell  salvage should be  facilitated with  use  of  Cell
savers  with/without  leukocyte  filters.  Blood  administration  may  be  associated  with  hy‐
perkalemia and hypocalcemia.
Bleeding during liver surgery could be either surgical, due to previous or acquired coag‐
ulation disturbances, or both. The preoperative INR has no predictive value in relation to
intraoperative  blood  loss  and  the  value  of  fresh  frozen  plasma (FFP)  administration  to
correct  abnormal  INR  values  is  debatable  and  may  even  increase  bleeding  due  to  the
volume load [51]. Intraoperative hemostasis panels consisting of INR, fibrinogen and pla‐
telet count, and platelet function assays for both platelet count and function, may help to
differentiate  between the  above.  A very useful  intraoperative  test  for  coagulation is  the
thromboelastograph  (TEG).  This  test  denotes  the  net  effect  of  pro  and  anti-coagulants
and pro and anti-fibrinolytic factors and the resulting clot tensile strength. It provides in‐
formation  on  the  rate  and  strength  of  clot  formation  and  also  clot  stability/fibrinolysis.
(Table 1)
Parameter Interpretation Preferred therapy for
abnormal values
R R is the time of latency from the time that the blood was
placed in the TEG® analyzer until the initial fibrin formation.
FFP
α The α-value measures the rapidity (kinetics) of fibrin build-up
and cross-linking and the speed of clot strengthening.
Cryoprecipitate
K K time is a measure of the rapidity to reach a certain level of
clot strength.
FFP
MA MA, or Maximum Amplitude, is a direct function of the
maximum dynamic properties of fibrin and platelet bonding
and represents the ultimate strength of the fibrin clot.
Platelet
Table 1. TEG Parameters
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Figure 1. The Normal TEG Graph
Figure 2. Prolonged Reaction Time
Figure 3. Reduced Angle
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In addition, it is possible to detect heparin-like activity and to measure functional fibrino‐
gen.(Figure 1-5,) Moreover, the only way to currently detect intraoperative hypercoagubility
is via TEG. (Figure 6) Thus, TEG may act to facilitate specific goal directed therapy. If fibri‐
nolysis is diagnosed on the TEG and it is causing clinically significant microvascular ooze,
small doses of epsilon aminocaproic acid (EACA) or tranexamic acid (TA) are suitable anti-
fibrinolytics. Factor VII has been used to control massive bleeding during liver surgery;
however, it has not proved to be consistently effective to control bleeding and is associated
with significant side effects. [52]
Transesophageal echocardiography (TEE) is a very useful cardiac monitoring tool to moni‐
tor function of the ventricles and assess intraoperative regional wall motion abnormalities
(RWMAs), especially in patients with CAD. The monitoring of right heart systolic function
is essential in patients with POPH. Moreover, it can be used effectively to assess volume sta‐
tus and guide fluid therapy.
9. Post-operative considerations
Surgery and anesthesia can further worsen hepatic function. Moreover, undiagnosed pre-
existing liver  disease is  often the cause of  hepatic  dysfunction postoperatively.  Depend‐
ing  upon  the  surgical  procedure,  one  may  observe  continued  “third  space“  losses..
Potential for renal dysfunction or failure as a result of surgery is exacerbated with preex‐
isting  liver  disease.  As  well,  preoperative  or  intraoperative  coagulopathy  can  continue
postoperatively or can develop during first 24-48 hrs after surgery secondary to worsen‐
ing hepatic dysfunction.
Postoperative jaundice occurs as a result of overproduction and under excretion of bilirubin,
direct hepatocellular injury, or extra-hepatic obstruction. [53] Multiple blood transfusions
can increase the levels of unconjugated bilirubin because approximately 10 % of stored
whole blood undergoes hemolysis within 24 hours of transfusion. Each 0.5 – 1 unit of blood
stored in CPDA-1 yields 7.5 g of hemoglobin, which is then converted to approximately 250
mg of bilirubin. [54] This may overwhelm the liver’s ability to conjugate and excrete biliru‐
bin. Immediate postoperative jaundice (< 3wks) can also occur due for multiple reasons in‐
cluding but not exclusive to hemolysis, anesthesia, hypotension, hypovolemia, drugs,
infection, sepsis, bleeding, resorption of hematoma, bile duct ligation or injury, hepatic ar‐
tery ligation, retained common bile duct stone, postoperative pancreatitis, Gilbert’s syn‐
drome, Dubin-Johnson Syndrome, inflammatory bowel syndrome, heart failure. [53]
Delayed postoperative jaundice (>3 wks) can be a result of drugs, blood transfusion, post-
intestinal bypass status and total parenteral nutrition. [53]
10. Postoperative pain relief role of epidural analgesia
Thoracic epidural analgesia provides excellent analgesia for liver resections. [55] The cathe‐
ter is usually inserted at the T6-T9 space. Ropivacaine or bupivacaine are common local an‐
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esthetics used with or without the addition of small amounts of opioids such as fentanyl,
sufentanil, hydromorphone or morphine. It also reduces the gastrointestinal paralysis com‐
pared with systemic opioids. [56]. There is benefit of using combined general and epidural
anesthesia in patients with high-risk surgery, but this has not been extensively studied in
hepatic surgery. The reasons are probably associated with the concerns with coagulation is‐
sues in this group. Additional concerns maybe harbored as neuroaxial blocks themselves are
associated with risks. Estimated risk of having serious neurological injury may be as high as
0.08 %.[57, 58]. Moreover, direct spinal cord injury can occur without paraesthesias, whereas
pain is more common in lesions affecting nerve roots. [59]. The incidence of persistent neu‐
rological deficit has been reported as 0.005-0.07 %. [60,61]. At our institution, we follow a
practice where time from anticoagulant drug administration to epidural catheter placement
is 3-5 days for warfarin, INR < 1.5, 4 hrs for heparin low dose subcutaneously, 12 hrs for low
molecular weight heparin (LMWH), 5 days for clopidogrel and zero for aspirin. The time
from epidural catheter removal to anticoagulant drug administration is at least 24 hrs for
warfarin, 2 hrs for low dose heparin and 6-8 hrs for LMWH.
It is essential to understand that the degree of underlying parenchymal disease is not the
only factor which is  responsible for perioperative coagulopathy. Other important factors
include amount of blood loss, dilution coagulopathy, amount and quality of residual liv‐
er parenchyma, its exposure to ischemia to name a few. [62-64]. Persistent pain or transi‐
ent  coagulopathy  may  cause  delayed  epidural  catheter  removal  in  patients  undergoing
partial  hepatectomy  [65].  The  risk  of  meningitis  or  epidural  abscess  is  in  the  range  of
0.0004-0.05% [66,67].
11. Liver – specific surgical procedures
Transjugular Intrahepatic Portosystemic Shunt Procedure (TIPS)
TIPS is a procedure used in patients with end stage liver disease to decrease portal pressure
and attenuate complications related to portal hypertension. It is usually done in the inter‐
ventional radiology suite. The goal of this procedure is diversion of portal blood flow into
the hepatic vein. The stent is passed through the internal jugular vein over a wire into the
hepatic vein, which is located using fluoroscopic guidance. This stent is then advanced
through the hepatic parenchyma into the portal vein. This will decompress the portal circu‐
lation. Usually, general anesthesia is requested for this procedure, as the radiologists prefer
that the patients do not move during this procedure and it may be prolonged. Sedation is
usually not preferred as there maybe potential respiratory depression in cirrhotic patients
with underlying pulmonary dysfunction or hypoxemia from hepatopulmonary syndrome.
Additionally, the presence of ascites may produce risk of aspiration. For this procedure, the
central venous pressure (CVP) is monitored. After the stent is placed, the portal pressures
are measured. Reduction of the difference between the two reflects the effectiveness of TIPS.
Potential complications of this procedure include pneumothorax with internal jugular vein
(IJV) cannulation, hematoma formation, inadvertent carotid puncture, cardiac arrhythmia
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with intracardiac catheter passage, acute life threatening hemorrhage with hepatic artery
puncture, hepatic capsular tear, extrahepatic portal venous puncture, development of pul‐
monary edema and congestive cardiac failure.
12. Radiofrequency Ablation (RFA) of hepatic tumors
Radiofrequency ablation of tumors up to 3 cm in size is currently used to treat non-resecta‐
ble malignant tumors. During this procedure, a high-frequency, alternating current is deliv‐
ered through a needle-like probe into the tumor, which induces coagulative necrosis of the
tumor and surrounding tissue.[68,69]. PFA is done either percutaneously or laparoscopical‐
ly. In a study which analyzed nationwide RFAs, it was found that procedure-specific com‐
plications were frequent (18.2 %), with transfusion requirements (10.7 %), intraoperative
bleeding (4.3 %), and hepatic failure (2.8 %) being the most common. Postoperative compli‐
cations were also common (12.0 %), with arrhythmias, heart failure, coagulopathy, and open
surgical approach acting as significant predictors. [70]
Transarterial Chemoembolization (TACE)
Usually,  an  adequate  amount  of  emulsion  containing  oil-based  contrast  agent  Lipiodol
and anticancer agents is injected through a catheter then the selected arteries are embol‐
ized  by  embolic  agents.  Superselective  TACE is  generally  used to  minimize  damage  to
non-tumorous  areas  by  using  a  microcatheter  to  embolize  only  the  cancerous  subseg‐
ment.[71-73] Epirubicin and cisplatin are commonly used as anticancer agents, and miri‐
platin,  a  new  platinum  drug,  came  into  use  in  2010.[74,75].  Indications  for  TACE  are
wide-ranging,  and the  procedure  is  generally  performed in  patients  with  hypervascular
hepatocellular cancer (HCC) who are not indicated for surgery or local  therapy for rea‐
sons  such  as  multiple  bilobar  HCC,  liver  dysfunction,  old  age  or  co-morbidity,  and  in
whom the first branch from the main portal vein is not occluded. In practice, this techni‐
que is commonly indicated for patients who are Child–Pugh class A or B with multiple
tumors  with  a  diameter  of  3  cm  or  more  or  with  four  or  more  HCC.  [76,77].  When
TACE is combined with RFA, there may be several advantages. For example, TACE de‐
creases  the  blood flow which  in  turn  reduces  the  heat  loss,  thus  increasing  the  size  of
the RFA ablative zone. In addition, the inclusion of TACE makes the evaluation of abla‐
tive margins easier, and enhances the control of satellite lesions.
Hepatic Resections
Liver resections can be done either open or robotic/laparoscopic. Hepatic resection proce‐
dures include partial resection, subsegmental resection, segmental resection, two segment
resection, extended two-segment resection or three-segment resections. Pre-operative assess‐
ment should include the evaluation of the risk assessment using the CTP or MELD score,
hepatic parenchymal function, and correction of severe anemia or coagulopathy, manage‐
ment of severe esophageal varices. The choice of anesthetic drugs as well as their doses
should be based on the above assessment. There is a risk of significant blood loss. Therefore,
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it may be prudent to secure large bore intravenous access and be prepared for rapid infusion
of colloids and crystalloids. Blood and blood products should be made available for perio‐
perative use. Control of bleeding during resection is usually done with pressure, coagula‐
tion and hilar clamping or via the Pringle maneuver. Hilar occlusion produces a minimal
increase in systemic arterial pressure, increase in systemic vascular resistance and a minimal
decrease in cardiac index. There may be risk of air embolism with extensive resection and
disruption of hepatic veins. Most surgeons request a low central venous pressure to facili‐
tate dissection and minimize blood loss from the hepatic vessels and vena cava. Postopera‐
tive concerns are similar to those in major abdominal surgery. Central neuroaxial analgesia
is not recommended if there is risk of coagulopathy which may result in hematoma forma‐
tion in the epidural or spinal space.
Donor Liver Hepatectomy
One method of expanding donor pool for liver transplantation is the use of living donor
grafts. Adult-to-adult living donor liver transplantation (LDLT) is a complex procedure that
poses serious health risks to and provides no direct health benefit for the donor. Because of
this uneven risk-benefit ratio, ensuring donor autonomy through informed consent is criti‐
cal. However, informed consent for LDLT is sub-optimal as donors do not adequately ap‐
preciate disclosed information during the informed consent process, despite United
Network for Organ Sharing/CMS regulations requiring formal psychological evaluation of
donor candidates. [78] Types of donor liver grafts can be left lobe, left lobe and caudate,
right lobe, extended right lobe and right lateral sector. After preoperative evaluation and
screening, a virtual resection and volume analysis is done using contrast enhanced comput‐
ed tomography (CT). These not only estimate SLV but can also determine segmental vol‐
ume, delineate surgical planes, define anatomical landmarks of hepatic vasculature and
biliary structures and calculate anticipated graft and remnant liver volumes post resection.
It is essential that the minimal donor remnant volume be at least 30% of the original volume.
Additionally, when right-lobe LDLT is planned, whether the middle hepatic vein (MHV)
should remain in the donor or be resected is controversial. The MHV primarily provides
various drainage of the right anterior lobe and segment IV. Most transplant surgeons prefer
to leave the MHV in the donor to avoid congestion of segment IV and reduce the risk of liv‐
er failure in the donor.[79] The anesthesia management is similar to that of hepatectomy. In
donors, several complications have been reported. In one study, right hepatectomy (resec‐
tion of segments 5–8) was done in 101 donors, left lobectomy (resection of segments 2–3) in
11 donors, and left hepatectomy (resection of segments 2–4) in one donor. Minor anesthetic
complications were shoulder pain, pruritus and urinary retention related to epidural mor‐
phine, and major morbidity included central venous catheter-induced thrombosis of the bra‐
chial and subclavian vein, neuropraxia, foot drop and prolonged postdural puncture
headache. One of 113 donors died from pulmonary embolism on the 11th postoperative day.
[80]. It was also observed that donor patients experienced significant postoperative pain de‐
spite the use of thoracic patient-controlled epidural analgesia (PCEA) infusion catheters as
compared to patients who had undergone major hepatic resection. This was attributed to the
longer surgical duration for donor hepatectomy and neuroplasticity which may play a role
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in exaggerated postoperative pain perception along with various psychological factors.[81].
It is also interesting to note that approximately 10% of donors had a platelet count < 150,000
x 109/liter, 2 to 3 years post-donation. [82]
13. Conclusion
Patients  with  liver  disease  are  at  increased  risk  for  both  perioperative  morbidity  and
mortality. They require delineation of the degree of liver dysfunction present prior to un‐
dergoing surgery and have outcomes that are primarily dictated by the degree of hepatic
dysfunction and type of surgery performed. They can certainly pose significant challeng‐
es for perioperative care.
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